#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma
1. Event-free survival at 2 years was longer in the neoadjuvant-adjuvant group vs the adjuvant-only group (72% vs 49%). 2. ...
Tag: anti-PD-1
Stereotactic body radiation does not improve outcomes in patients with advanced Merkel cell carcinoma receiving nivolumab and ipilimumab
1. Objective response rate was not significantly different in patients treated with stereotactic body radiotherapy compared to those without. 2. ...
Neoadjuvant celmiplimab is associated with pathologic response in cutaneous squamous cell carcinoma
1. After neoadjuvant treatment with celmiplimab, half of the patients were found to have a complete pathological response 2. Almost ...
Cemiplimab treatment of recurrent cervical cancer is associated with longer overall survival
1. Overall survival is longer in patients treated with cemiplimab as compared to chemotherapy. 2. Fewer adverse effects are associated ...
#VisualAbstract: Addition of radiotherapy to anti-PD-1 therapy does not improve survival in advanced mucosal melanoma
Click to read this study in the European Journal of Cancer.
#VisualAbstract: Nivolumab plus ipilimumab may be less effective in females with melanoma compared to males
Click to read this study in JAMA Network Open.
#VisualAbstract: High-dose glucocorticoids may be detrimental for the management of patients with advanced melanoma expieriencing immune-related adverse events
Click to read the study in Clinical Cancer Research.
#VisualAbstract: Greater immunosuppression is associated with worse outcomes in patients with advanced melanoma receiving ipilimumab and anti-PD-1 therapy
Click to read the study in the European Journal of Cancer.
Checkpoint inhibitors show some benefit in patients with microsatellite stable metastatic colorectal cancer without liver metastases
1. In this retrospective cohort study investigating targeted therapy of programmed cell death receptor 1 and programmed cell death ligand ...
Adjunctive nivolumab reduces risk of death and progression of gastric adenocarcinoma compared to chemotherapy alone
1. Overall survival and progression-free survival were higher for patients on nivolumab plus chemotherapy compared to chemotherapy alone. 2. Severe ...